Trials / Suspended
SuspendedNCT03779100
Lenvatinib Plus PD-1 Antibody for Unresectable ICC
Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Antibody for Unresectable Intrahepatic Cholangiocarcinoma
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Shi Ming · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with unresectable intrahepatic cholangiocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | 12 mg (or 8 mg) once daily (QD) oral dosing. |
| DRUG | PD-1 antibody | 3mg/kg intravenously every 2 weeks |
Timeline
- Start date
- 2018-12-17
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2018-12-19
- Last updated
- 2019-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03779100. Inclusion in this directory is not an endorsement.